Jason Oliver

Senior Director Of Business Development at Ascendia

Jason Oliver has over 15 years of experience in business development and has held various senior leadership positions in the pharmaceutical industry.

Most recently, they served as the Senior Director of Business Development at Ascendia, where they played a crucial role in driving the company's growth and strategic partnerships.

Prior to that, Jason was the Director of Business Development at Almac Group, where they successfully identified new business opportunities and managed client relationships.

Before joining Almac Group, Jason founded and led OrLive LLC for four years, overseeing all aspects of the company's operations.

Jason also held senior director roles at Altasciences and BioDuro, where they specialized in business development for clinical development and manufacturing organizations, providing services in drug discovery, dosage form development, and GMP manufacturing.

Jason's earlier experience includes roles at Pfizer, QSpharma, Norwich Pharmaceuticals, Patheon, and Aptuit, where they demonstrated their expertise in developing and managing client relationships, marketing, and technical sales.

Throughout their career, Jason Oliver has consistently demonstrated their ability to drive business growth, establish strategic partnerships, and provide innovative solutions to their clients in the pharmaceutical industry.

Jason Oliver attended The College of New Jersey from 1989 to 1995, where they obtained a Bachelor of Science degree in Biology. Additionally, from 1991 to 1994, they attended Mercer County Community College and earned an Associate degree in Science, Architecture. Jason also holds YMCA and US Swimming Coaching Certifications from USA Swimming, although the specific month and year of obtaining these certifications are not provided.

Location

Trenton, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Ascendia

1 followers

Ascendia Pharmaceuticals offers a comprehensive suite of pre-formulation for preclinical- and clinical-stage drug candidates. It specializes in improving the solubility and bioavailability of poorly water-soluble drugs using its suite of nanotechnology platforms. Ascendia formulates products for injectable, oral, and topical routes ofadministration. The company has three technology platforms - EmulSol for producing nano-emulsions, AmorSol for creating amorphous solid dispersions, and NanoSol for formulating nano-particles.